STOCK TITAN

Quince Therapeutics Inc - QNCX STOCK NEWS

Welcome to our dedicated news page for Quince Therapeutics (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quince Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quince Therapeutics's position in the market.

Rhea-AI Summary
Quince Therapeutics, Inc. (QNCX) provides an update on its development pipeline and financial results for the fourth quarter and fiscal year ended December 31, 2023. With the acquisition of EryDel S.p.A., the company focuses on Phase 3 development for EryDex to treat Ataxia-Telangiectasia. They have $75.1 million in cash to complete Phase 3 trials and expand into new indications. The NEAT clinical trial for A-T patients is progressing towards enrollment with potential NDA submission in 2026. Quince aims to redefine chronic corticosteroid therapy and explore new applications for its AIDE technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
-
Rhea-AI Summary
Quince Therapeutics, Inc. (QNCX) forms a Scientific Advisory Board with renowned experts to advance its Phase 3 asset, EryDex, for rare neurodegenerative disease treatment. The SAB includes experts in biochemistry, neurology, immunology, and hematology to support pipeline expansion and innovative drug delivery technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
management
-
Rhea-AI Summary
Quince Therapeutics, Inc. (Nasdaq: QNCX) appoints Dr. Rajiv Patni, a seasoned biopharma industry expert, to its Board of Directors. Dr. Patni brings 25 years of global product development experience, focusing on rare diseases. His appointment signals Quince's strategic growth plans and potential commercial expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
management
Rhea-AI Summary
Quince Therapeutics, Inc. (Nasdaq: QNCX) announced that their CEO and CMO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will be accessible via a live webcast on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
conferences
-
Rhea-AI Summary
Quince Therapeutics, a late-stage biotechnology company (Nasdaq: QNCX), announced that Dirk Thye, M.D., the CEO and CMO, will participate in two investor events in San Francisco in January 2024 to discuss innovative drug delivery technology for rare disease therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
conferences
-
Rhea-AI Summary
Quince Therapeutics completes acquisition of EryDel to develop drug delivery technology for rare neurodegenerative disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
Rhea-AI Summary
Quince Therapeutics announces FDA lifting partial clinical hold on EryDel's IND application for EryDex, a Phase 3 asset. Market represents $1+ billion estimated peak sales opportunity. Quince intends to advance global Phase 3 NEAT trial for potential treatment of Ataxia-Telangiectasia. No approved treatments currently available. Acquisition of EryDel pending regulatory approvals and expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
-
Rhea-AI Summary
Quince Therapeutics appoints Charles S. Ryan as President, focusing on legal activities and IP portfolio. Pending acquisition of EryDel S.p.A., Ryan will oversee integration of financial and operational activities. Ryan's expertise expected to enhance efficiency and effectiveness. Quince and EryDel assets offer opportunity to advance treatment for pediatric patients with Ataxia-Telangiectasia. Ryan brings extensive background in pharmaceuticals and biotechnology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
conferences
Rhea-AI Summary
Quince Therapeutics, Inc. (Nasdaq: QNCX) announces acquisition of EryDel SpA, a late-stage biotech company, and its lead asset EryDex, utilizing autologous intracellular drug encapsulation (AIDE) technology for slow release of steroids. EryDel stockholders to own 16.7% of the combined company and entitled to up to $485 million in milestone payments. Transaction expected to close in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.22%
Tags
Quince Therapeutics Inc

Nasdaq:QNCX

QNCX Rankings

QNCX Stock Data

40.75M
27.05M
17.06%
28.16%
4.3%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
South San Francisco

About QNCX

cortexyme is developing therapeutics based on data supporting a new theory of the cause of alzheimer's and other degenerative disorders. cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. the target has been validated in a number of animal models and cortexyme is currently moving a proprietary small molecule towards human clinical testing.